According to a recent LinkedIn post from SpliceBio, the company plans an active week of engagement with the biotech community at two European industry events. The post highlights that Chief Business Officer Gerard Caelles is scheduled to present its 3rd generation protein splicing technology focused on applications in the central nervous system at the 1st Annual European Neuroscience Innovation Forum.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The same post notes that CEO Miquel Vila-Perello, Ph.D., is expected to deliver a company overview at the BioCapital Europe Conference, a venue that typically attracts investors and industry partners. These appearances suggest SpliceBio is prioritizing visibility among potential partners and capital providers, which could support future financing, collaborations, and strategic positioning in the neuroscience and gene therapy segments.
For investors, the emphasis on “3rd generation” protein splicing in CNS indicates a focus on differentiated platform capabilities that may be relevant to diseases with high unmet need. While the post does not disclose clinical or financial milestones, increased participation in high-profile European forums may signal that the company is preparing to showcase its progress and potentially lay groundwork for partnership deals or future funding initiatives.